Purpose: The combined effect of hyperthermia and radiation therapy can be quantified by an enhanced equivalent radiation dose (EQD). Uncertainties in hyperthermia treatment planning and adjustments during treatment can impact achieved EQD. We developed and compared strategies for EQD optimization of radiation therapy plans, focusing on robustness against common adjustments.
Methods And Materials: Using Plan2Heat, we computed preplanning hyperthermia plans and treatment adjustment scenarios for 3 cervical cancer patients. We imported these scenarios into RayStation 12A for optimization with 4 different strategies: (1) conventional radiation therapy optimization prescribing 46 Gy to the planning target volume (PTV), (2) nominal EQD optimization using the preplanning scenario, targeting uniform 58 Gy in the gross tumor volume (GTV), keeping organs at risk doses as in plan 1, (3) robust EQD optimization, as plan 2 but adding adjusted scenarios for optimization, and (4) library of plans (4 plans) with strategy 2 criteria but optimizing on 1 adjusted scenario per plan. We calculated for each radiation therapy plan EQD distributions for preplanning and adjusted scenarios, evaluating each combination of GTV coverage and homogeneity objectives.
Results: EQD95% increased from 49.9 to 50.9 Gy in strategy 1 to 56.1 to 57.4 Gy in strategy 2 with the preplanning scenario, improving homogeneity by ∼10%. Strategy 2 demonstrated the best overall robustness, with 62% of all GTV objectives within tolerance. Strategy 3 had a higher percentage of coverage objectives within tolerance than strategy 2 (68% vs 54%) but a lower percentage for uniformity (44% vs 71%). Strategy 4 showed a similar EQD95% and homogeneity for adjusted scenarios than strategy 2 for a preplanning scenario. D0.1% (radiation dose received by the 0.1% most irradiated volume) for organs at risk was increased by strategies 2 to 4 by up to ∼6 Gy.
Conclusions: EQD optimization enhances EQD levels and uniformity compared with conventional optimization. Better overall robustness is achieved by optimizing the preplanning hyperthermia plan. Robust optimization improves coverage but reduces homogeneity. A library of plans ensures coverage and uniformity when dealing with adjusted hyperthermia scenarios.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2024.07.2146 | DOI Listing |
Cancer J
January 2025
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
There is major interest in deintensifying therapy for isocitrate dehydrogenase-mutant low-grade gliomas, including with single-agent cytostatic isocitrate dehydrogenase inhibitors. These efforts need head-to-head comparisons with proven modalities, such as chemoradiotherapy. Ongoing clinical trials now group tumors by intrinsic molecular subtype, rather than classic clinical risk factors.
View Article and Find Full Text PDFCancer J
January 2025
From the Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
There has been a significant paradigm shift in the clinical management of lower-grade glioma patients given the recent updates to the 2021 World Health Organization classification along with long-term results from randomized phase III clinical trials. As a result, we are now better able to diagnose and assign patients to the most appropriate treatment course. This review provides a comprehensive summary of the most robust and reliable molecular biomarkers for adult lower-grade gliomas and discusses current challenges facing this patient population that future correlative biology studies combined with advancements in technologies could help overcome.
View Article and Find Full Text PDFCancer J
January 2025
From the Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Purpose: Chemoradiation-induced lymphopenia is common and associated with poorer survival in multiple solid malignancies. However, the association between chemoradiation-related lymphopenia and survival outcomes in rectal cancer is yet unclear. The objective of this study was to evaluate the prognostic impact of lymphopenia and its predictors in patients with rectal cancer undergoing neoadjuvant chemoradiation.
View Article and Find Full Text PDFCancer Chemother Pharmacol
January 2025
Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models.
Methods: To establish dose and tolerability of elimusertib with FOLFIRI, a Bayesian Optimal Interval trial design was pursued.
Childs Nerv Syst
January 2025
The Geoffrey Jefferson Brain Research Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Background: Atypical teratoid/rhabdoid tumours (ATRTs) are malignant central nervous system tumours, typically presenting in the posterior fossa of very young children. Prognosis remains poor despite current therapy, while tumorigenesis implicates both genomic and epigenetic dysregulation. Primary diffuse leptomeningeal (PDL) ATRT, characterised by the absence of an intraparenchymal mass lesion, is seldom reported but appears associated with a dismal outcome.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!